Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376613699> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W4376613699 endingPage "101379" @default.
- W4376613699 startingPage "101379" @default.
- W4376613699 abstract "In the phase III, randomized, open-label KEYNOTE-119 (NCT02555657) study, second- or third-line treatment with pembro monotherapy did not significantly improve OS vs single-agent chemo treatment of physician’s choice (TPC) in patients (pts) with mTNBC, although the pembro treatment effect increased with increasing PD-L1 enrichment. In this exploratory analysis, we evaluated the association of T-cell-inflamed gene expression profile (GEP) with clinical outcomes from KEYNOTE-119. Pts with centrally confirmed mTNBC, ECOG PS ≤1, and 1-2 prior systemic treatments for metastatic breast cancer were randomized 1:1 to pembro 200 mg Q3W for up to 35 cycles or TPC (capecitabine, eribulin, gemcitabine, or vinorelbine) per local guidelines. Tumor RNA profiling was conducted on the RNA-seq platform (Illumina, San Diego, CA). Association of GEP with clinical outcomes was evaluated by logistic regression (best objective response [BOR] per RECIST v1.1) and Cox proportional hazards models (PFS and OS) with baseline adjustment for ECOG PS; 95% CIs for BOR were estimated using the Clopper and Pearson method. As of April 11, 2019, GEP data for 333 pts (pembro, n=177; TPC, n=156) were available for analysis. GEP was significantly associated with improved BOR, PFS, and OS in pts treated with pembro but not TPC (Table). HR for OS was 0.77 (95% CI, 0.58–1.04) in pts with GEP non-low (≥1st tertile) and 1.72 (1.15–2.55) in pts with GEP low (<1st tertile). No association was seen between BRCA/HRD status and treatment response. These findings suggest a positive association between GEP and clinical outcomes in pts with mTNBC who are treated with pembro, with a more favorable treatment effect in the GEP-enriched population. Results may help inform future analyses of outcomes by biomarker status in this population." @default.
- W4376613699 created "2023-05-17" @default.
- W4376613699 creator A5006642161 @default.
- W4376613699 creator A5010031732 @default.
- W4376613699 creator A5010278367 @default.
- W4376613699 creator A5016015665 @default.
- W4376613699 creator A5018682015 @default.
- W4376613699 creator A5019282569 @default.
- W4376613699 creator A5036301363 @default.
- W4376613699 creator A5036420234 @default.
- W4376613699 creator A5042452774 @default.
- W4376613699 creator A5051629490 @default.
- W4376613699 creator A5051908149 @default.
- W4376613699 creator A5052104589 @default.
- W4376613699 creator A5054654521 @default.
- W4376613699 creator A5061102317 @default.
- W4376613699 creator A5061867713 @default.
- W4376613699 creator A5065172378 @default.
- W4376613699 creator A5070245248 @default.
- W4376613699 creator A5077520870 @default.
- W4376613699 creator A5080084854 @default.
- W4376613699 creator A5089861374 @default.
- W4376613699 date "2023-05-01" @default.
- W4376613699 modified "2023-10-15" @default.
- W4376613699 title "190MO Association of 18-Gene expression profile (GEP) with clinical outcomes in patients with metastatic triple-negative breast cancer (mTNBC) treated with pembrolizumab (Pembro) or chemotherapy (Chemo) in KEYNOTE-119" @default.
- W4376613699 doi "https://doi.org/10.1016/j.esmoop.2023.101379" @default.
- W4376613699 hasPublicationYear "2023" @default.
- W4376613699 type Work @default.
- W4376613699 citedByCount "0" @default.
- W4376613699 crossrefType "journal-article" @default.
- W4376613699 hasAuthorship W4376613699A5006642161 @default.
- W4376613699 hasAuthorship W4376613699A5010031732 @default.
- W4376613699 hasAuthorship W4376613699A5010278367 @default.
- W4376613699 hasAuthorship W4376613699A5016015665 @default.
- W4376613699 hasAuthorship W4376613699A5018682015 @default.
- W4376613699 hasAuthorship W4376613699A5019282569 @default.
- W4376613699 hasAuthorship W4376613699A5036301363 @default.
- W4376613699 hasAuthorship W4376613699A5036420234 @default.
- W4376613699 hasAuthorship W4376613699A5042452774 @default.
- W4376613699 hasAuthorship W4376613699A5051629490 @default.
- W4376613699 hasAuthorship W4376613699A5051908149 @default.
- W4376613699 hasAuthorship W4376613699A5052104589 @default.
- W4376613699 hasAuthorship W4376613699A5054654521 @default.
- W4376613699 hasAuthorship W4376613699A5061102317 @default.
- W4376613699 hasAuthorship W4376613699A5061867713 @default.
- W4376613699 hasAuthorship W4376613699A5065172378 @default.
- W4376613699 hasAuthorship W4376613699A5070245248 @default.
- W4376613699 hasAuthorship W4376613699A5077520870 @default.
- W4376613699 hasAuthorship W4376613699A5080084854 @default.
- W4376613699 hasAuthorship W4376613699A5089861374 @default.
- W4376613699 hasBestOaLocation W43766136991 @default.
- W4376613699 hasConcept C121608353 @default.
- W4376613699 hasConcept C126322002 @default.
- W4376613699 hasConcept C143998085 @default.
- W4376613699 hasConcept C2780110267 @default.
- W4376613699 hasConcept C2780258809 @default.
- W4376613699 hasConcept C530470458 @default.
- W4376613699 hasConcept C71924100 @default.
- W4376613699 hasConceptScore W4376613699C121608353 @default.
- W4376613699 hasConceptScore W4376613699C126322002 @default.
- W4376613699 hasConceptScore W4376613699C143998085 @default.
- W4376613699 hasConceptScore W4376613699C2780110267 @default.
- W4376613699 hasConceptScore W4376613699C2780258809 @default.
- W4376613699 hasConceptScore W4376613699C530470458 @default.
- W4376613699 hasConceptScore W4376613699C71924100 @default.
- W4376613699 hasIssue "1" @default.
- W4376613699 hasLocation W43766136991 @default.
- W4376613699 hasOpenAccess W4376613699 @default.
- W4376613699 hasPrimaryLocation W43766136991 @default.
- W4376613699 hasRelatedWork W1999292713 @default.
- W4376613699 hasRelatedWork W2027260716 @default.
- W4376613699 hasRelatedWork W2139975046 @default.
- W4376613699 hasRelatedWork W2317787856 @default.
- W4376613699 hasRelatedWork W2376078656 @default.
- W4376613699 hasRelatedWork W2382613782 @default.
- W4376613699 hasRelatedWork W2385290594 @default.
- W4376613699 hasRelatedWork W2554176272 @default.
- W4376613699 hasRelatedWork W3044626609 @default.
- W4376613699 hasRelatedWork W3186761709 @default.
- W4376613699 hasVolume "8" @default.
- W4376613699 isParatext "false" @default.
- W4376613699 isRetracted "false" @default.
- W4376613699 workType "article" @default.